Investors Urged to Lead Lawsuit Against Aardvark Therapeutics
Rosen Law Firm has alerted purchasers of Aardvark Therapeutics stock about a critical deadline to lead a securities fraud class action. The lawsuit alleges misrepresentations concerning the company's IPO and subsequent period.
Rosen Law Firm, a global investor rights law firm, has notified purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD) securities about an important lead plaintiff deadline of October 13, 2026. This deadline is for individuals who acquired Aardvark stock in connection with its February 2025 initial public offering (IPO) or between February 13, 2025, and May 14, 2026.
The class action lawsuit alleges that Aardvark Therapeutics and its executives made materially false and misleading statements and failed to disclose adverse information about the company's business, operations, and prospects. Specifically, the suit claims that the company misled investors regarding the safety profile of its drug candidate, ARD-101.
According to the complaint, defendants allegedly failed to disclose that ARD-101 was less safe than represented, leading to overstated clinical, regulatory, and commercial prospects for the drug. Investors who purchased Aardvark securities during the specified period are urged to seek representation.
Rosen Law Firm is offering compensation without out-of-pocket fees or costs through a contingency fee arrangement for eligible investors. Those wishing to serve as lead plaintiff must file a motion with the court by the October 13, 2026 deadline. The firm encourages investors to contact them for more information about the class action and their rights.